Sensory Nerve Neuropeptides (Substance P and CGRP) Drive Skin Barrier Repair After Damage | Research

The takeaway

TRPV1-positive sensory nerves and their neuropeptides (substance P and CGRP) are essential for epidermal barrier repair after tape stripping-induced disruption in mice.

TRPV1 nerves + neuropeptides
Substance P and CGRP from sensory nerves drive skin barrier repair after tape stripping damage

What the researchers found

TRPV1-positive sensory nerves and neuropeptides (substance P and CGRP) are required for epidermal barrier repair after tape stripping, with involvement of filaggrin biosynthesis in the restoration process.

Why it matters

Understanding how nerves help repair skin could transform treatment of barrier-deficient skin conditions like eczema, psoriasis, and dry skin. If neuropeptides like substance P and CGRP drive barrier restoration, they could become therapeutic targets for skin repair.

The numbers in context

TRPV1-positive sensory nerves identified as participants in barrier repair; filaggrin (encoded by Flg gene) production involved in the process.

How the study worked

Animal study in mice using tape stripping to disrupt the epidermal barrier. Assessed TRPV1-positive sensory nerve involvement, neuropeptide (substance P, CGRP) contribution, and filaggrin expression during barrier repair.

Who was studied

Mice with tape stripping-induced epidermal barrier disruption

What this study cannot tell us

Mouse study — skin structure and innervation differ between mice and humans. Tape stripping is a simplified model that doesn't fully replicate clinical barrier damage. Specific neuropeptide receptor pathways not fully dissected. Quantitative contribution of each neuropeptide not determined.

How to read the evidence

Moderate evidence — well-designed animal study with mechanistic investigation. Provides strong basic science foundation but requires human validation.

When this study was published

Published in 2024. Advances understanding of the neuro-dermatology axis in skin barrier function.

The bigger picture

The skin-nerve axis is increasingly recognized as critical for skin health beyond just sensation. This study adds barrier repair to the growing list of skin functions that sensory nerves and their peptide mediators regulate — connecting neuroscience to dermatology in clinically meaningful ways.

Questions still open

Could topical substance P or CGRP analogs accelerate skin barrier repair in eczema patients?
Do TRPV1 receptor blockers (used for pain) impair skin barrier healing as an unintended side effect?
Is the nerve-mediated barrier repair pathway disrupted in atopic dermatitis?

Common questions

How do nerves help heal skin?

Sensory nerves in the skin release small signaling molecules called neuropeptides — specifically substance P and CGRP. This study found these neuropeptides actively help rebuild the skin's protective outer layer after it's been damaged, showing that nerves do more than just feel — they help the skin repair itself.

Could this lead to new treatments for eczema or dry skin?

Potentially — if neuropeptides help restore the skin barrier, then creams or treatments containing these peptides (or drugs that boost their release) could help conditions where the skin barrier is weak, like eczema. Conversely, some pain medications that block these nerve signals might accidentally slow skin healing.

Read the original research

TRPV1-positive sensory nerves and neuropeptides are involved in epidermal barrier repair after tape stripping in mice.

The Journal of allergy and clinical immunology, 153(3), 868-873.e4

View on PubMed ↗Publisher’s paper ↗

Citation

Usui, Kenji; Nakashima, Chisa; Takahashi, Sonoko; Okada, Takaharu; Ishida, Yoshihiro; Nakajima, Saeko; Kitoh, Akihiko; Nomura, Takashi; Dainichi, Teruki; Honda, Tetsuya; Katsumoto, Rumi; Konishi, Noriko; Matsushita, Mutsuyoshi; Otsuka, Atsushi; Kabashima, Kenji. (2024). TRPV1-positive sensory nerves and neuropeptides are involved in epidermal barrier repair after tape stripping in mice.. The Journal of allergy and clinical immunology, 153(3), 868-873.e4. https://doi.org/10.1016/j.jaci.2023.11.024